Here’s why the Patrys (ASX:PAB) share price is tumbling 16% today

Investors tend to keep a keen eye on clinical trial progress.

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

Patrys Limited (ASX: PAB) shares are tumbling in late morning trade. At the time of writing, the Patrys share price has slumped 16.33% following the company’s latest announcement.

Below we take a look at the ASX healthcare company’s update on its clinical trial preparation.

What update did Patrys report?

The Patrys share price is tanking after the company reported there were unanticipated delays in its PAT-DX1 clinical trial program.

Across a number of pre-clinical studies, PAT-DX1 has demonstrated significant ability to kill cancer cells.

In February, Patrys reported it had selected a “stable, high-yielding cell line suitable for the commercial production of clinical-grade PAT-DX1”. The company’s commercial contract manufacturer used this cell line to prepare the production and purification processes at its facility.

While the required materials were ordered 6 months in advance, the company reported that the COVID-19 pandemic has disrupted global reagent production and supply chains. Due to the proprietary nature of the reagents, Patrys said it is unable to source them from other suppliers.

Patrys now expects the engineering run for PAT-DX1 will be pushed back to the fourth quarter of this year. This will delay the start of its GMP toxicology studies to the first quarter of 2022, “pending the availability of GMP grade PAT-DX1”.

The company anticipates it will now submit a Human Research Ethics Application (HREA) for the phase 1 clinical trial in the second half of 2022.

Commenting on the delay, Patrys CEO James Campbell said it was obviously disappointing for the company and its loyal shareholders. He stressed that the delay is “based solely on global supply chains, not technical obstacles”.

Campbell added:

The recent data from ongoing pre-clinical studies has been extremely positive and has highlighted the many ways our deoxymabs may be able to improve the health of patients with a range of difficult to treat cancers.

We continue to work with our global suppliers to prepare for and initiate the first PAT-DX1 clinical trial in late 2022. In addition, we will continue to pursue a range of unique development opportunities for both PAT-DX1 and PAT-DX3.

Patrys share price snapshot

Despite today’s slide, the Patrys share price remains up more than 300% over the past 12 months, well outpacing the 28% gains posted by the All Ordinaries Index (ASX: XAO).

Year to date, the Patrys share price also continues to charge ahead, up 105% in 2021.

Should you invest $1,000 in Patrys right now?

Before you consider Patrys, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Patrys wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares